It has been suggested that neonates with KCNQ2, KCNQ3 or SCN2a epilepsy respond well to treatment with low-dose sodium channel blockers, such as carbamazepine or oxcarbazepine [17,31,85,87]. The gene discussed is SCN2A; the disease is epilepsy.